James Palacino

James Palacino

Company: Orum Therapeutics

Job title: Vice President


Development of TPD² – Combining the Power of Protein Degradation With the Precision of Antibodies for Next-Generation ADCs 10:10 am

Examining the potency of GSPT1 degrader as a payload Discussing improved pharmacokinetic properties Outlining improved safety and tolerabilityRead more

day: Scientific Program Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.